Form D Summary: Oragenics $4.67 million Financing. Michael Sullivan Submitted Jul 13 Form D

Biotechnology Oragenics Inc - Michael Sullivan

Oragenics Financing

Oragenics Inc, Corporation just released form D regarding $4.67 million equity financing. This is a new filing. Oragenics was able to finance itself with $4.67 million. That is 100.00% of the fundraising offer. The total financing amount was $4.67 million. The fundraising form was filed on 2016-07-13. The reason for the financing was: unspecified.

Oragenics is based in Florida. The firm’s business is Biotechnology. The form D was signed by Michael Sullivan Chief Financial Officer. The company was incorporated more than five years ago. The filler’s address is: 4902 Eisenhower Blvd., Suite 125, Tampa, Fl, Florida, 33634. Alan Joslyn is the related person in the form and it has address: 4902 Eisenhower, Suite 125, Tampa, Fl, Florida, 33634. Link to Oragenics Filing: 000120919116132554.

Analysis of Oragenics Offering

On average, startups in the Biotechnology sector, sell 73.77% of the total offering amount. Oragenics sold 100.00% of the offering. Could this mean that the trust in Oragenics is high? The average financing size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 51.52% bigger than the average for companies in the Biotechnology sector. The minimum investment for this fundraising was set at $0. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Oragenics Also

The Form D signed by Michael Sullivan might help Oragenics Inc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment